February 2, 2017 10:49 AM EST
News Briefing

J&J makes new in­vest­ments in mi­cro­bio­me R&D; UK’s Ar­ix out to raise £100 mil­lion for new biotech in­vest­ments

Shehla Shakoor

Managing Director

• J&J is mak­ing some new in­vest­ments in mi­cro­bio­me re­search, in­clud­ing adding Caelus Health to its J&J In­no­va­tion port­fo­lio. “These col­lab­o­ra­tions and in­vest­ments will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Eli Lil­ly taps Ama­zon Phar­ma­cy to dis­pense its pre­scrip­tion med­i­cines

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times